This initiative involves the development of an immunohistochemistry assay for assessing programmed death-ligand 1 (PD-L1) expression in tumor tissues. The assay helps identify patients who may respond to immune checkpoint inhibitor therapies, enabling personalized treatment strategies in various cancers.